Form 4: Nurix Therapeutics CSO Reports Routine Stock Sale for Tax Obligations

Nurix Therapeutics' Chief Scientific Officer, Gwenn Hansen, reported the acquisition of common stock through RSU vesting and a subsequent sale of shares to cover tax withholding obligations.

Summary

• Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc. (NRIX), reported transactions on July 30, 2025, involving the vesting of Restricted Stock Units (RSUs) and a subsequent sale of common stock.
• Acquired a total of 11,815 shares of common stock through the vesting of RSUs at an exercise price of $0 per share.
• Disposed of 4,308 shares of common stock at a weighted average sale price of $12.011 per share, with individual sales ranging from $11.78 to $12.315.
• The sale was a mandatory 'sell to cover' transaction to satisfy tax withholding obligations in connection with the RSU vesting, not a discretionary trade.
• Following these reported transactions, Gwenn Hansen beneficially owns 69,023 shares of Nurix Therapeutics common stock directly.
• Additionally, Gwenn Hansen beneficially owns 70,106 unvested Restricted Stock Units (RSUs).

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax purposes related to RSU vesting, which is a common and non-discretionary event for insiders. It does not indicate a change in sentiment towards the company or its prospects.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates continued employment and commitment of a key executive to the company.
• The acquisition of 11,815 shares of common stock through RSU vesting at a $0 cost basis increases the executive's direct equity stake in the company.

Negatives

• The sale of 4,308 shares, while for tax purposes, represents a reduction in the executive's direct common stock holdings.

Industry Context

This Form 4 filing details a routine insider transaction related to equity compensation. Such 'sell to cover' transactions are common across all industries for executives receiving Restricted Stock Units (RSUs) or stock options, as they are a standard mechanism for satisfying tax liabilities upon vesting or exercise.

Stakeholder Impact

• Shareholders: The transaction is a routine 'sell to cover' and is unlikely to have a significant impact on the company's share price or shareholder value. It represents a minor increase in the public float.

Next Steps

• Continued vesting of remaining Restricted Stock Units (RSUs) according to their respective schedules, subject to the Reporting Person's continued provision of services to the Issuer.

Key Dates

Recommendation

This Form 4 filing details a routine 'sell to cover' transaction by a Chief Scientific Officer to satisfy tax obligations upon RSU vesting. Such non-discretionary sales are common and do not typically signal a change in the insider's view of the company's prospects. Therefore, the filing itself does not provide new information that would warrant a change in investment recommendation.

Keywords

Nurix Therapeutics, NRIX, Form 4, Insider Trading, Stock Sale, RSU Vesting, Gwenn Hansen, Chief Scientific Officer, Equity Compensation